GlassScriptPhysician profile
Michelle Flores
NPI 1629522438
$14,996.80
in general payments reported to CMS, 2019-2025
29 companies · $2,911 in 2025
The $2,911 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,512 · 2022: $2,837 · 2023: $4,028 · 2024: $3,708 · 2025: $2,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $200 · Travel and Lodging: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,270.17 |
| Education | $200.25 |
| Travel and Lodging | $177.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,306.61 | 2021-2025 | |
| Janssen Biotech, INC. | $1,404.85 | 2021-2025 | Tremfya, Na |
| Incyte Corporation | $1,321.34 | 2021-2025 | Opzelura, Iclusig |
| Genzyme Corporation | $983.35 | 2021-2025 | |
| Leo Pharma INC. | $721.59 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $662.23 | 2021-2025 | |
| Ucb, INC. | $583.74 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $581.85 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $527.25 | 2021-2025 | Blu-U, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $433.12 | 2022-2025 | Sotyktu |
| Amgen INC. | $407.93 | 2021-2025 | Otezla, Otezla |
| Organogenesis INC. | $402.57 | 2021-2023 | Puraply |
| Abbott Laboratories | $396.10 | 2022-2023 | Ensite, Na, Advisor |
| Lilly USA, LLC | $351.56 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $338.10 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $280.34 | 2021-2025 | Nemluvio, Epsolay, Twyneo |
| Arcutis Biotherapeutics, INC. | $261.47 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $241.75 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $147.63 | 2021 | |
| Abiomed | $122.57 | 2024 | Impella |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $115.46 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Janssen Scientific Affairs, LLC | $85.33 | 2024 | Tremfya |
| Botanix Sb INC | $71.12 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $70.10 | 2021-2023 | Valchlor |
| Almirall LLC | $67.17 | 2021-2025 | Klisyri |
| Organon LLC | $38.39 | 2025 | Vtama |
| Biofrontera INC. | $30.96 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Boston Scientific Corporation | $27.94 | 2025 | Rezum Generator |
| Strata Skin Sciences, INC. | $14.38 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.